CHARMD

TOP

• Short name: J Infect Dis
• References:
• -A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000).
• -Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. (Sep 2002).
• -Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016).
• -Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997).
• -Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006).
• -Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. (Sep 2024).
• -Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019).
• -Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007).
• -Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002).
• -Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024).
• -Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022).
• -Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997).
• -Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022).
• -Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients. (Mar 2020).
• -Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003).
• -Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014).
• -Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. (Dec 2001).
• -Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003).

Mutations: